Member Info for kenny100

Andrew you found what I read, well done mate...................
Looking good........... LOL

In £ millions of lost production............

Cargo ship stranded in Suez Canal blocking shipping worldwide
By Jon Gambrell and Samy Magdy, Associated Press 3 hrs ago

https://www.youtube.com/user/OTCMarketsTV/videos

https://www.otcmarkets.com/

https://en.wikipedia.org/wiki/Over-the-counter_(finance)#:~:text=Over-the-counter%20%28OTC%29%20or%20off-exchange%20trading%20is%20done%20directly,transparency%2C%20and%20maintaining%20the%20current%20market%20price%20.

Going forward, the company is looking at potential “third-party sales agreements” for Apollon products in countries such as South Africa and Greece, says Jacobs.

Corporate developments may include ‘up listing’ here in the UK and taking a stock market quote in the US, most likely on the OTC QB.

Jacobs says the company has news flow “coming thick and fast” after the RTO.

Still paying billions to the EU reduce it to zero and give the NHS workers a pay rise........... IMHO

https://www.wallstreet-online.de/aktien/powerhouse-energy-group-aktie/kurse

https://www.youtube.com/watch?v=VrKW58MS12g

Up 36 views in one hour................. :+)

https://www.youtube.com/watch?v=BGXxfkwQfQg

44 views only..................

https://www.youtube.com/watch?v=rg4jeqKtZs4

From 20 mins in 1.2 million per day $6.00 million US per week..... £4.3 million per week ball park....

https://www.youtube.com/watch?v=Z2w5W2FEQmY

DATE
16.03.21
A full spectrum of opportunities for Apollon Formularies

“…Investors will do very well over the next five years if they invest in Apollon…”

With the plethora of cannabis-related listings across UK stock exchanges, the accessibility to consumer CBD and cannabinoid focused companies has increased and investors are holding the likes of Kanabo and Cellular Goods in their ‘green’ portfolios.

It’s less likely they are holding stock in soon-to-be listed Apollon Formularies as the book is already closed after a substantially oversubscribed fundraise.

Head of Business Development Stene Jacobs explains that a lot of capital has already been ‘sunk’ into Apollon so the company didn’t need a huge quantum, but for those who missed out “there is a second round of fundraising that will happen within 2021.”
Apollon is a full spectrum medical cannabis company which makes use of THC in its formulations. That’s the part which makes the consumer high, but more importantly it’s the key component that makes the cannabis medication work.

The only other company permissioned to use THC in its formulas and have FDA-approved prescription cannabidiol medicine is GW Pharmaceuticals which has been bought by Jazz Pharmaceuticals for $7.2 billion.
In addition to its CBD product range, Apollon too includes THC in its medical formulations and has federally approved licences which include its coveted R&D licence which gives it a legal route to conducting physician-supervised human treatments. The company has already done so on close to 500 patients with what Jacobs describes as “phenomenal results.”

Bringing the company to the Aquis Exchange via a reverse takeover is founder and physician Dr. Stephen Barnhill aka ‘The Doc.’ He migrated from producing medicine for big pharma to what at the time was the more niche cannabis treatments that he engaged with when his mother became unwell.
Guiding him through the listing process is Rod McIlree who at the age of 29 years was the youngest person to list a company on the ASX. McIlree has launched multiple companies since then and is currently chairman of Bluejay Mining. (JAY.L)

Listen to Stene talk to Sarah Lowther about the company’s USP’s, how 3D printing will revolutionise medication delivery, its unique-in-the-world R&D licence which allows Apollon to use formulations on patients and the altruism that will be the founder’s swan song and a money maker for investors.

In case anyone missed.................

Buying interest27 Oct '20
I can probably shed some light on this folks. The company has been generating some interest amongst subscribers to the Michael Walters investment site in the past few days, where there is a new thread relating to this company. Changes are expected imminently which may revive it's fortunes. I myself listened in on an investment call hosted by Dr Barnhill of Apollon only last week, along with CEO of another well-known AIM company (not DL). Sorry but MW is a paid forum so I cannot divulge and you would have to subscribe if you want to read up more on what is currently being discussed. It's well worth the money if you do, not just because of the thread on AgriAg.

Apollon is a medical cannabis company based in Jamaica, where it holds a suite of licences and is fully regulated, allowing the company to work with full spectrum oils inclusive of THC. The company plans, using its own formulations, to develop medicines for conditions that afflict humans in the modern world.

It aims to create a globally recognised brand synonymous with quality, consistent potency on a range of products for a range of conditions withing the medical cannabis space.

Apollon Formularies will through its subsidiary Apollon Formularies Jamaica Ltd (a fully licensed full spectrum medical cannabis company), develop, market, distribute and sell full spectrum (inclusive of THC) products in the legal hemp and medical cannabis industry. It is currently producing pharmaceutical, nutraceutical and other medical cannabis related products, including 3D printed sublingual, suppositories and capsules. Apollon Formularies was established to advance the current significant commercial opportunities in the legal medical cannabis markets globally.

Apollon Formularies Jamaica Limited (“AFJ”) is licensed to operate at the Federal level in Jamaica and hold the following licences and approvals:

Medically supervised treatments
Cultivate cannabis
Retail dispensary license
Retail therapeutic distribution
Extraction processing facility
“Tier 3” conditional cultivation approval expected soon
Licences include R&D using THC
Together these licences create a vertically integrated full spectrum (inclusive of THC) medical cannabis company both in Jamaica and to the international market via legal export from Jamaica to countries where the law allows import of medical cannabis products.

https://www.apollon.org.uk/about

Apollon is a medical cannabis company based in Jamaica, where it holds a suite of licences and is fully regulated, allowing the company to work with full spectrum oils inclusive of THC. The company plans, using its own formulations, to develop medicines for conditions that afflict humans in the modern world.
Apollon
www.apollon.org.uk/

Apollon Formularies
@apollon_uk
·
1h
Interested in #MedicalCannabis stocks? Apollon #APOL will be joining
@AquisStockEx
soon and will be one of the very few listed European companies able to undertake medically supervised treatments using newly developed formulations inclusive of #THC...

https://total-market-solutions.com/2021/03/investing-in-the-uks-small-cap-medicinal-cannabis-stocks/

https://www.apollon.org.uk/products/3d-printer/

Apollon Formularies


Another intriguing name to look out for is Apollon Formularies, a medical cannabis company based in Jamaica preparing for listing on the Aquis Exchange.

Interviewed by Sarah Lowther for TMS earlier this month, Apollon’s Head of Business Development Stene Jacobs said that although the book is already closed after a substantially oversubscribed fundraise, for those who missed out ‘there is a second round of fundraising that will happen within 2021’.

Apollon uses machine learning AI technology to offer personalised clinical treatment, analysing data to identify the best combinations of cannabinoids to target and optimise prescriptions for each customer, producing tailored solutions for nausea, pain, sleep, anti-inflammatory, seizures, and appetite disorders. The company holds a suite of licences and is fully regulated, allowing the company to work with products that include elements of THC in addition to CBD: there is evidence that THC also has highly effective medicinal properties. The company’s technologies are overseen by CEO Dr Stephen Barnhill, an early pioneer in the use of AI techniques in medicine, primarily in the field of cancer diagnostics.
Apollon runs an in-patient medical cannabis treatment facility in Jamaica, where more than 400 patients have been treated in the past year, and which the company plans to expand to 130-person capacity. Another Apollon innovation is a patent pending 3D pharmaceutical printer, designed to overcome import and export regulations on cannabinoids and THC. Purchasing companies – if fully licensed – can order specific formulation ‘recipes’ to be emailed over to a printer, allowing Apollon formulations to be printed ‘in house’ using bio ink.

Apollon Formularies Retweeted
Total Market Solutions
@TMSreach
Time to invest in the UK’s Small Cap Medicinal #Cannabis Stocks?

“...Backed by a growing consumer base, increasing recognition from financial regulators and governments the sector is on a strong upwards trajectory…”

#APOL #CBX #FFWD #KNB #LIFE